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To design successful vaccines for chronic diseases,
an understanding of memory CD8+ T cell responses
to persistent antigen restimulation is critical. How-
ever, most studies comparing memory and naive
cell responses have been performed only in rapidly
cleared acute infections. Herein, by comparing the
responses ofmemory and naive CD8+ T cells to acute
and chronic lymphocytic choriomeningitis virus in-
fection, we show that memory cells dominated over
naive cells and were protective when present in
sufficient numbers to quickly reduce infection. In
contrast, when infection was not rapidly reduced,
because of high antigen load or persistence, memory
cells were quickly lost, unlike naive cells. This loss of
memory cells was due to a block in sustaining cell
proliferation, selective regulation by the inhibitory
receptor 2B4, and increased reliance on CD4+ T cell
help. Thus, emphasizing the importance of designing
vaccines that elicit effective CD4+ T cell help and
rapidly control infection.
INTRODUCTION
Memory CD8+ T cells can provide efficient protection to reinfec-
tion resulting from their increased cytotoxic potential, cytokine
secretion, and ability to respond to reinfection faster than naive
CD8+ T cells. Recent studies have focused on better delineating
what qualities memory cells need in order to be protective and
highly functional, as well as how to better design vaccines to
elicit memory cells with these properties (Ahmed and Gray,
1996; Appay et al., 2008; Harty and Badovinac, 2008; Kaech
et al., 2002b; Prlic et al., 2007). Because memory CD8+ T cellscan provide quick and effective elimination of intracellular path-
ogens, vaccines designed to generate virus-specific memory
CD8+ T cells represent an attractive strategy for combating
persistent human viral and intracellular bacterial infections
such as HIV, HCV, and tuberculosis. Importantly, multiple stu-
dies have indicated that virus-specific CD8+ T cell function and
proliferation are associated with decreased SIV or HIV viral
loads, thus indicating that virus-specific CD8+ T cells can help
control SIV and HIV infection (Ahlers and Belyakov, 2010; Bang-
ham, 2009; Goulder and Watkins, 2008). However, studies have
not been rigorously performed comparing the protective abilities
and qualities ofmemory versus naive CD8+ T cells during chronic
infections. Because chronic antigen stimulation has been shown
to be detrimental to CD8+ T cells, understanding the response of
memory CD8+ T cells to persistent antigen restimulation is
important for rational vaccine design for chronic infections.
During chronic antigen stimulation, CD8+ T cells undergo
exhaustion, characterized by decreased proliferative capacity,
loss of cytokine secretion, reduced cytotoxic killing abilities,
and phenotypic changes, such as an increase in inhibitory mole-
cule expression (Shin and Wherry, 2007; Wherry et al., 2003a).
Upregulation of multiple inhibitory molecules has been shown
to play a major role in the process of CD8+ T cell exhaustion
during chronic infection. In particular, the inhibitory molecule
programmed death 1 (PD-1) has been shown to play a central
role in the process of CD8+ T cell exhaustion, and blocking
PD-1 can partially rescue exhausted CD8+ T cells by increasing
both their numbers and antiviral function (Barber et al., 2006;
Velu et al., 2009). Furthermore, other inhibitory receptors, such
as lymphocyte activation gene (Lag-3) and T cell immunoglobulin
and mucin domain-containing molecue-3 (Tim-3) have been
shown to synergize with PD-1, and coblockade studies have re-
sulted in enhanced restoration of function to exhausted CD8+
T cells (Blackburn et al., 2009; Jin et al., 2010). Another inhibitory
molecule upregulated by exhaustedCD8+ T cells is 2B4 (CD244),
but the role of this molecule in T cell exhaustion is not well under-
stood. Most research on 2B4 has focused on its’ role on naturalImmunity 35, 285–298, August 26, 2011 ª2011 Elsevier Inc. 285
Immunity
Memory CD8+ T Cells in Acute and Chronic Infectionkiller cells and recent reports have provided conflicting views as
to whether 2B4 plays an inhibitory or stimulatory role on CD8+
T cells (Bengsch et al., 2010; Blackburn et al., 2009; Raziorrouh
et al., 2010; Rey et al., 2006; Waggoner et al., 2010; Wang et al.,
2010; Wherry et al., 2007). Our understanding of CD8+ T cell
exhaustion and the roles of inhibitory receptors in this process
are mainly based on studies of the primary T cell response. How-
ever, because vaccination results in a pool of pathogen-specific
memory CD8+ T cells, it is important to better understand how
inhibitory molecules affect the secondary response of pre-
existing memory CD8+ T cells in the setting of chronic infection.
Another important aspect of T cell vaccine design is under-
standing the role of CD4+ T cell help in the generation of func-
tional CD8+ T cell responses. Whereas CD4+ T cell help has
been shown to be important during CD8+ T cell primary re-
sponses to generate quality memory cells in multiple acute viral
and bacterial infections (Harty and Badovinac, 2008; Northrop
and Shen, 2004; Williams et al., 2006), the relative importance
of CD4+ T cell help in primary and secondary CD8+ T cell re-
sponses in acute versus chronic infection has not been ad-
dressed. Therefore, understanding both the response ofmemory
CD8+ T cells to persistent antigen restimulation and the role of
CD4+ T cell help may be key in designing successful vaccines
for chronic diseases. In the present study we addressed these
questions by using the lymphocytic choriomenengitis virus
(LCMV) model to compare naive and memory CD8+ T cell
responses during acute and chronic infection.
RESULTS
Memory Cells Are Selectively Lost during High Antigen
Load or Antigen Persistence
To examine the effects of chronic versus acute antigen re-expo-
sure on naive and memory CD8+ T cells, we utilized the mouse
LCMV CD8+ TCR transgenic P14 system (cells specific for
LCMV Db-restricted epitope GP33-41). This transgenic system
allowed us to eliminate differences in TCR avidity and specificity
between naive and memory cells and allowed for comparisons
on a per cell basis. Furthermore, by cotransferring both the
memory and naive cells into the same mice, we were able to
eliminate possible differences in environment. We altered the
duration of antigen stimulation by infecting mice with either the
Armstrong strain (Arm) of LCMV, which results in an acute
infection that is cleared by day 8–10 postinfection (p.i.), or
clone-13 strain (cl-13), which differs from Arm by only two amino
acids and results in a highly disseminated viral infection with
2 months of viremia (Ahmed et al., 1984; Wherry et al.,
2003a). The memory P14 cells used in these adoptive transfer
experiments were highly functional memory cells from LCMV
Armstrong immune mice that produced TNF-a, IL-2, and IFN-g
upon ex vivo restimulation with their cognate GP33 peptide.
Furthermore, 80%–90% of these memory cells had the central
memory phenotype CD44hiCD127hiCD62Lhi (see Figures S1A
and S1B available online). By 7 days postinfection (p.i.), the
transferred memory T cells (secondary effectors) dominated
over the transferred naive T cells (primary effectors) in the blood
during acute LCMV infection, as previously described (Figure 1A;
Badovinac et al., 2003; Grayson et al., 2002; Jabbari and Harty,
2006; Masopust et al., 2006). In striking contrast, when the mice286 Immunity 35, 285–298, August 26, 2011 ª2011 Elsevier Inc.were infected with the LCMV chronic strain, cl-13, primary
effectors outnumbered secondary effectors at day 7, and this
difference became even more drastic as the infection pro-
gressed (Figure 1A). Importantly, similar results were obtained
when the cells were transferred separately into different mice
(data not shown). Moreover, transferred memory cells were
also rapidly lost, unlike naive cells, in the tissues after chronic
infection (p < 0.01 in spleen and p < 0.005 in liver and bone
marrow) (Figures 1B and 1C). These data show that secondary
effectors are more detrimentally impacted by high antigen load
or antigen persistence than are primary effectors.
We wanted to eliminate the possibility that the loss of
secondary effector T cells during chronic infection was due to
differences in tropism between the Arm and cl-13 strains of
LCMV. Although these two strains differ by only two amino acids,
the increased receptor binding affinity of the cl-13 strain alters
the viral tropism, allowing it to infect cell types that the Arm strain
does not (Durbeej et al., 1998; Mueller et al., 2007; Sevilla et al.,
2000). Therefore, we transferred naive and memory P14 T cells
into mice and then infected them with either a low or high dose
of LCMV cl-13. Mice infected with a low dose of cl-13 (2 3 102
pfu) had no detectible viremia at day 4 p.i. and the infection
was rapidly cleared as an acute infection, unlike the viral persis-
tence seen in mice infected with the high dose (2 3 106 pfu) of
cl-13 (data not shown). Infection with the low dose of cl-13
resulted in the secondary effector P14 outnumbering the primary
effectors (Figures 1B and 1C), similar to that in acute Arm infec-
tion. Furthermore, by altering the dose and route of Armstrong
infection, we changed the length of antigen presence by a few
days, but this also resulted in differential survival or loss of trans-
ferred memory CD8+ T cells. With the typical acute dose of Arm
(2 3 105 pfu) given i.p. or i.v., secondary effector cells predomi-
nated, as shown previously. However, when the higher dose of
Arm (2 3 106 pfu) was given i.v., the situation was changed,
and the primary effector cells dominated over the secondary
effector cells (Figure S1C). It should be noted that this effect
was less drastic than that seen after chronic cl-13 infection,
where antigen amounts were much higher and the duration of
viral persistence was longer. Taken together, these data show
that high antigen load or persistence rather than viral tropism
affect memory cell expansion and/or survival.
Next, we asked whether this observation was applicable to
nontransgenic memory CD8+ T cells. We sorted and transferred
either LCMV-specific DbGP33 tetramer+ memory CD8+ T cells
(specific for the same epitope as P14 T cells) or memory P14
T cells along with an equal number of naive P14 T cells. We
observed the same phenomenon of selective loss of thememory
cells with both the nontransgenic memory T cells and the trans-
genic memory P14 cells during chronic infection, whereas both
persisted during acute infection (Figure S1D, data not shown).
Central and Effector Memory Cells Generated by
Multiple Vaccines Are Lost during Antigen Persistence
Because different vaccines or viruses can result in memory cells
of varying phenotypes and function, we asked whether the initial
vaccine or virus used to create the memory cells impacted
the ability of memory cells to persist during chronic antigen
exposure. To address this, we generated memory P14 cells
with multiple vaccines or viruses: LCMV, an adenovirus vector
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Figure 1. Naive and Memory CD8+ T Cell Responses during Acute versus Chronic Infection
13 103 of each memory (Thy1.1+Thy1.2+) P14 and naive P14 T cells (Thy1.1+Thy1.2) were cotransferred into naive B6 mice. On the following day the mice were
infected with either LCMV Arm (acute) or LCMV cl-13 (chronic). Blood was taken at days 7, 14, 21, and 32 postinfection.
(A) Percent of transferred memory and naive P14 cells in the blood after infection.
(B andC) Cells were cotransferred as above andmice were infected with either an acute (23 102 pfu) or chronic (23 106 pfu) dose of LCMV cl-13. Representative
dot plots (B) and numbers (C) of transferred cells in the tissues day 14 p.i.
Results representative of two to six independent experiments with four to sixmice per group. Statistical comparisonswere performedwith the unpaired Student’s
t test; *p < 0.05, **p < 0.01. Error bars represent SEM. See also Figure S1.
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Memory CD8+ T Cells in Acute and Chronic Infectionexpressing the LCMV glycoprotein (GP), or vaccinia virus ex-
pressing the LCMV GP33 epitope. It is important to note that
memory CD8+ T cells can be divided into two main subsets,
central and effector memory T cells, that have different prolifer-
ative abilities and effector properties upon restimulation, at
differing anatomical locations (Masopust et al., 2001; Sallusto
et al., 1999; Wherry and Ahmed, 2004; Wherry et al., 2003b).
To control for differences resulting from altered ratios of central
to effector memory CD8+ T cells generated by different viruses
or vaccines, we sorted the memory P14 cells into CD62Lhicentral memory (Tcm) and CD62Llo effector memory (Tem) cell
populations and cotransferred each of them individually with
naive P14 T cells (Figure 2A). Because Tcm cells have more
proliferative capacity than do Tem cells (Wherry et al., 2003b),
we found, as expected, that only Tcm cells dominated the naive
P14 cells during acute infection (Figures 2B–2D). However, after
chronic infection, both Tcmand Tem cells were preferentially lost
in the blood and tissues no matter which vaccine or virus was
used to initially create them (Figures 2B–2D). Thus, even purified
highly proliferative central memory CD8+ T cells were unable toImmunity 35, 285–298, August 26, 2011 ª2011 Elsevier Inc. 287
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Figure 2. Memory Cells Are Preferentially Lost during Chronic Antigen Exposure, Regardless of the Vaccine or Virus Used to Generate the
Memory Cells
Memory P14s (Thy1.1+Thy1.2) were generated by either Arm, Ad-5GP, or VV-33 infection. At day 46 p.i., memory cells were sorted based on CD62L expression.
Tcm (CD62L+) and Tem (CD62L) cells were each cotransferred with naive P14s (Thy1.1+Thy1.2+) and the mice were infected the following day with an acute
(2 3 102 pfu) or chronic (2 3 106 pfu) dose of LCMV cl-13.
(A) Experimental set-up.
(B and C) Representative flow plots of Tcm memory and naive P14 cells in the blood at day 14 p.i. (B) and numbers in the tissues at day 26 p.i. (C).
(D and E) Representative flow plots of Tem memory and naive P14 cells in the blood at day 14 p.i. (D) and numbers in the tissues at day 26 p.i. (E).
Results representative of six mice per group. *p < 0.05, **p < 0.01, ***p < 0.005. Error bars represent SEM. See also Figure S2.
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Memory CD8+ T Cells in Acute and Chronic Infectionpersist during chronic antigen stimulation. Furthermore, this is
applicable to memory cells generated by an adenovirus vector,
vaccinia virus, or LCMV Arm.
Last, to verify that the loss of secondary effectors is related to
antigen persistence and not something specific to the LCMV
system, we cotransferred naive and memory P14 cells and
immunized the mice with a persistent adenovirus 5 vector
expressing the LCMV glycoprotein. Intramuscular injection of
E1-deleted replication-deficient adenoviral vectors expressing
a transgene into mice results in detectable amounts of the
transgene for 5–6 weeks postinjection, indicating that these
vectors result in persistence of a low amount of protein antigen
(Tatsis et al., 2007). As seen after chronic LCMV infection,
memory cells were selectively lost during persistent adenovirus
infection (Figure S2), thus verifying that this phenomenon is not
specific to the LCMV system but is related to antigen chronicity.
Secondary Effectors Have a Block in Sustaining
Cell Proliferation
We wanted to determine whether the relative decrease in
numbers of secondary effectors to primary effectors was due to
a difference in initial recruitment of the cells, increased cell death,
and/or decreased proliferation of the secondary effector P14
T cells. By day 4 during acute LCMV infection, there were already
significantly more secondary effectors than primary effectors in
the tissues (p < 0.01 in spleen, p < 0.05 in liver) (Figures 3A and
3B). In contrast, at day 4 during chronic LCMV infection, there
were equal numbers of transferred memory and naive cells in
the spleens and livers (Figures 3A and 3B). This indicates that
although secondary effectors are selectively lost during antigen
persistence, their initial recruitment is similar to primary effectors.
To understand the possible role that cell proliferation and death
play in the loss of secondary effectors, mice were given BrdU
i.p. for 6 hr at days 6 and 8 postinfection with chronic LCMV and
cell proliferation was assessed by BrdU incorporation. By day 6
p.i., there was a reduction in the proliferation of the secondary
effectors, with only 21% of the secondary effectors incorpo-
rating BrdU compared to 39% of primary effectors (Figure 3C),
an effect that was maintained at day 8 p.i. (20% of secondary
and43%of the primary effectors were BrdU+) (Figure 3C). Inter-
estingly, cell death of the secondary effectorswas either similar, at
day 6 p.i. (14% of secondary and 18% of primary effectors
were 7AAD+), or reduced, at day 8 p.i. (12% of secondary and
25%of the primary effectorswere 7AAD+), compared to primary
effectors. This finding indicates that thedecreasednumberof sec-
ondary effectors is due to decreased proliferative abilities com-
pared to primary effectors in the context of antigen persistence.
We next sought to characterize the major differences between
naive and memory cells at a molecular level. We compared the
gene expression profiles of primary effector (naive) CD8+ T cells
with secondary effector (memory) CD8+ T cells at day 8 postin-
fection in the setting of chronic infection, and we tested for
enrichment of classes of genes corresponding to major biolog-
ical processes in each cell type. We found that there was highly
significant upregulation of sets of genes related to cell cycle and
proliferation in primary effectors compared to secondary effec-
tors in chronic infection (Figure 3E; Table S1). In addition, genes
related to RNA processing, amino acid synthesis, mitochondrial
metabolism, and DNA repair were highly upregulated in primaryversus secondary effector T cells in chronic infection. In
contrast, there was significant upregulation of cell cycle-depen-
dent kinase inhibitors (CDKis) CDKN1A (p21/Cip) (p = 0.002,
FDR = 0.18) and CDKN2B (p15) (p = 0.002, FDR = 0.18) in
secondary effectors compared to primary effectors in chronic
infection. Some evidence of increased expression of prolifera-
tion-associated genes was also evident in the primary versus
secondary effector comparison in acute infection; however,
CDKis were not upregulated in secondary effectors in acute
infection. Thus in chronic infection, the global expression
pattern of primary effectors was consistent with more robust
proliferation and metabolic activity than secondary effector
CD8+ T cells.
2B4 Selectively Regulates Memory Cells during
Chronic Infection
We then asked whether the preferential loss of memory cells
during chronic infection could be attributed to increased CD8+
T cell exhaustion of the memory cells compared to naive cells.
From day 5 to day 14 after chronic infection, both the primary
and secondary P14 T cells acquired a decreasing potential to
make TNF-a, IFN-g, and IL-2 after ex vivo peptide restimulation
with cognate GP33 peptide, indicating that both are undergoing
the typical CD8+ T cell exhaustion seen in chronic infection (Fig-
ure S3). To evaluate the development of the exhausted state at
a global level, we analyzed gene expression profiles from
primary and secondary CD8+ T cells at day 8 after acute or
chronic infection. We compared these profiles with published
microarray data of exhausted CD8+ T cells at D21 during
chronic LCMV infection (Wherry et al., 2007). Gene set enrich-
ment analysis showed highly significant upregulation of the ex-
hausted CD8+ T cell gene signature during chronic infection in
both the primary and secondary effectors (Figures 4A and 4B).
The most enriched genes from the exhausted signature in both
primary and secondary effectors were highly similar (Figure 4C)
and, with few exceptions, these genes were expressed at the
same magnitude among the primary and secondary effector
samples (Table S2). These findings suggest that both memory
and naive cells develop the molecular and functional properties
of T cell exhaustion to a similar degree and argue against
a more extreme exhausted phenotype in secondary effectors.
In order to identify candidate mechanisms involved in the
selective loss of secondary effectors in chronic infection, we
identified genes selectively upregulated in that population
(compared to primary effectors after chronic infection and to
primary and secondary effectors after acute infection). Among
the most differentially upregulated genes in secondary effectors
in chronic infection, we found several inhibitory receptors
(Figures 4D and 4E). Whereas the genes encoding PD-1 and
Lag-3 were expressed at equivalent levels in primary and
secondary effectors during chronic infection (p > 0.05), 2B4
and Tim-3were among themost highly upregulated in secondary
effectors (4.4-fold increase in 2B4 in secondary versus primary
effectors in chronic infection, p = 0.002; and 2.2-fold increase
in Tim-3, p = 0.002) (Figure 4E). It is important to note that all
of these inhibitory receptors were also highly expressed on
primary effectors after chronic infection, as compared to acute
infection. However, expression of these receptors was highest
on secondary effectors after chronic infection (Figure 4E).Immunity 35, 285–298, August 26, 2011 ª2011 Elsevier Inc. 289
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Figure 3. Initial Recruitment of Naive andMemory Cells Is Similar during Chronic Infection, but Memory Cells Have a Block in Sustaining Cell
Proliferation
(A and B) 53 103 of each memory (Thy1.1+Thy1.2) and naive (Thy1.1+Thy1.2+) P14 cells were transferred into B6 mice and the mice were infected the following
day with either an acute (2 3 102 pfu) or chronic (5 3 106 pfu) dose of LCMV cl-13.
(A and B) Numbers (A) and representative flow plots (B) of naive and memory P14s in the spleens and livers at day 4 p.i.
(C) 1 3 103 of each memory (Thy1.1+Thy1.2+) and naive (Thy1.1+Thy1.2) P14 cells were transferred into B6 mice and the mice were infected the following day
with 2 3 106 cl-13. Percent of P14 cells that are BrdU+ 6 hr after BrdU i.p. injection at days 6 and 8 p.i.
(D) Modular view of genes upregulated in primary versus secondary effectors at day 8 after chronic infection. Genes upregulated in primary effectors were tested
for enrichment with the KEGG collection of annotated gene sets corresponding to major biological processes via gene set enrichment analysis (GSEA). The
expression of genes contained in the leading edges of gene sets that were significantly enriched are displayed as a heatmap matrix and clustered by gene
(column) and row (gene set). A cluster of gene sets related to RNA processing are colored purple; nucleotide synthesis, yellow; DNA replication, blue; metabolism,
orange; and proliferation, green. Genes contained in the proliferation module are listed in green. See also Table S1.
(E) Relative gene expression values of CDKNA1 (p21/Cip) (p = 0.002) and CDKNB2 (p15) (p = 0.002).
Results representative of two or three independent experiments with four to six mice per group (A–C). *p < 0.05, **p < 0.01, ns = p > 0.05 (A–C). Error bars
represent SEM.
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memory cells during antigen persistence, we performed in vivo
functional studies. Blocking PD-1 or Lag-3 signaling by
administering PD-L1 or Lag-3 blocking antibodies to mice in-
fected with chronic LCMV after adoptive cotransfer of memory
and naive P14 cells did not lead to the increased survival of
memory cells over naive cells (data not shown). Therefore,
although the inhibitory receptors PD-1 and Lag-3 play a role in
the functional exhaustion of both the secondary and primary
virus-specific effector CD8+ T cells during persistent antigen
stimulation, these receptors do not inhibit memory cells more
than naive cells. These results were consistent with the micro-
array data, because neither PD-1 nor Lag-3 was differentially
expressed between primary and secondary effector CD8+
T cells during chronic infection. Thus, PD-1 and Lag-3 do not
appear to play a role in the selective loss of secondary effectors
during chronic antigen stimulation.
Next, because Cd244 (2B4) was the inhibitory receptor gene
most differential upregulated in secondary compared to primary
effectors, we sought to determine whether the increased expres-
sion of Cd244 played a functional role in the loss of secondary
effectors during chronic infection. Because the available anti-
bodies used to block 2B4 in vitro are cell depleting in vivo, we
bred 2B4-deficient mice (Cd244/) with LCMV-specific P14
TCR transgenic mice to obtain 2B4-deficient P14 TCR trans-
genic mice (Cd244/ P14). We transferred memory and naive
wild-type or Cd244/ P14 T cells into naive mice and then
subsequently infected the mice with chronic LCMV. The pheno-
type and function of the naive Cd244/ P14 cells versus wild-
type naive P14 cells as well as the memory Cd244/ P14 cells
versus wild-type memory P14 cells were identical pretransfer
(data not shown). Interestingly, the transferred 2B4-deficient
memory cells were able to persist during chronic infection, unlike
wild-type (2B4-sufficient) cells (p < 0.01 at days 7 and 14, and p <
0.005 at day 23), and there was no observable difference
between the wild-type and 2B4-deficient naive cells (p > 0.05)
(Figures 4F and 4G). These data document a role for 2B4 in
the preferential loss of secondary effectors during antigen
persistence.
Memory Cells Are More Dependent on CD4+ T Cell Help
than Naive Cells during Antigen Persistence
We have established that inhibitory receptors play an enhanced
role in regulating memory cells during chronic infection. There-
fore, we next wanted to find a way to overcome the increased
regulation of these cells and enhance memory cell persistence
during chronic infection. Because CD4+ T cell help has been
shown to be important for CD8+ T cell function during viral infec-
tions (Harty and Badovinac, 2008; Northrop and Shen, 2004;
Wherry, 2011; Williams et al., 2006), we investigated whether
increased LCMV-specific CD4+ T cell help could rescue the
transferred memory cells during chronic infection. To answer
this question, we cotransferred LCMV GP61 epitope-specific
CD4+ T cells (Smarta) at the time of naive and memory CD8+
T cell cotransfer into normal CD4+ intact B6 mice. After infection
with chronic LCMV, secondary effectors in the mice receiving
Smarta cells outnumbered the primary effectors in multiple
tissues and the blood (p < 0.005) (Figures 5A–5C). Overall, this
resulted in a greater than 3-fold increase of memory cells in thespleens of mice receiving Smarta cells compared to those
without, although the number of naive cells remained similar
between the two groups during chronic infection (p < 0.005) (Fig-
ure 5B). These data indicate selective rescue of the transferred
memory cells. The increase in secondary effectors was seen
only during chronic infection, because neither the primary nor
secondary effector CD8+ T cell numbers changed with Smarta
cell cotransfer during acute infection (Figures 5A–5C). Further-
more, the rescue of theCD8+ T cells by cotransfer of Smarta cells
during chronic infection was not due to reduced viral loads at this
early time point after CD4+ T cell transfer, as shown by the fact
that both the chronically infected mice receiving Smarta cells
and those without Smarta cells had serum viral titers between
105 and 106 log10 pfu/ml at day 6.5 p.i. (data not shown). Thus,
our data indicate that during prolonged high antigen stimulation,
the memory CD8+ T cells are more reliant on CD4+ T cell help
than naive cells.
To understand the mechanism in which CD4+ T cell help
rescues memory CD8+ T cells during chronic infection, we first
asked whether this rescue was linked to the increased immuno-
regulation of memory cells by 2B4. To address this, we assessed
2B4 expression on memory CD8+ P14 T cells in chronically in-
fected mice after transfer of Smarta cells. 2B4 was expressed
at equivalent levels onmemory CD8+ T cells at day 6.5 postinfec-
tion whether or not they were rescued by added CD4+ T cell help
(Figure S4A), thereby suggesting that 2B4 does not play a role in
the rescue of memory cells by CD4+ T cell help during chronic
infection; instead, these are two independent mechanisms.
Second, because CD40 and CD40L interactions have been
shown to be important for CD4+ T cell help of CD8+ T cells (Bour-
geois et al., 2002; Grewal and Flavell, 1998), we asked the ques-
tion of whether CD40:CD40L interactions were playing a role
in the rescue of memory CD8+ T cells by CD4+ T cell help. We
cotransferred memory and naive CD8+ P14 T cells along with
Smarta cells and blocked this pathway by the use of an antibody
that blocks CD40L (MR1). We administered MR1 1 day before
infection with chronic LCMV (D1), on the day of infection
(D0), and every 3 days thereafter and sacrificed the mice at
day 6.5 postinfection. The blockade of CD40:CD40L interactions
in mice that did not receive Smarta cells resulted in a slight
reduction of both memory and naive P14 T cells, because it
inhibits endogenous CD4+ T cell help (Figure 5D). However, the
number of naive P14 T cells did not differ between the mice
treated with MR1 and those treated with MR1 that received
Smarta cells. The blockade of CD40:CD40L interactions resulted
in a significant reduction in the expansion of memory P14 T cell
numbers seen after Smarta cell transfer (p < 0.001), showing
a mechanism in which CD4+ T cell help rescue. Furthermore,
blockade of CD40L did not significantly affect Smarta cell
expansion at this early time point (Figure S4B). Thus, our data
indicate that during prolonged high antigen stimulation, memory
CD8+ T cells are more reliant on CD4+ T cell help than naive cells
and that CD40:CD40L interactions may be involved.
The Ability of Naive and Memory CD8+ T Cells to Control
Acute versus Chronic Infection
In order to better understand how the increased regulation of
memory cells during chronic infection impacts protective immu-
nity, we assessed the ability of memory and naive cells to controlImmunity 35, 285–298, August 26, 2011 ª2011 Elsevier Inc. 291
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Figure 4. The Role of 2B4 in Regulating Virus-Specific Memory CD8+ T Cells during Chronic Infection
(A and B) Gene set enrichment analysis (GSEA) of a signature of genes associated with exhausted CD8+ T cells in the rank ordered list of genes differentially
expressed in (A) primary effectors at day 8 in chronic versus acute infection and (B) secondary effectors at day 8 in chronic versus acute infection.
(C) Genes at the leading edge of enrichment in primary effector GSEA (green set) and secondary effector GSEA (orange set) are largely overlapping. See also
Table S2.
(D) Genes differentially expressed at day 8 in secondary effectors in chronic infection compared to secondary effectors in acute infection and primary effectors in
either infection. Each column represents an individual sample, each row a gene, and cells were colored to indicate relative expression. Top 200 genes
upregulated or downregulated are shown, ranked by the signal-to-noise metric; 2B4 (Cd244) is indicated.
(E) Relative expression values of Cd244, Tim-3, Lag-3, and PD-1.
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Figure 5. The Role of CD4+ T Cell Help in Primary and Secondary Responses during Acute versus Chronic Infection
1 3 103 of each memory (Thy1.1+Thy1.2+) and naive (Thy1.1+Thy1.2) P14s were cotransferred with or without 1 3 106 LCMV-GP61-specific CD4+ T cells
(Smartas) into naive mice. The next day mice were infected with either an acute (2 3 102) or chronic (2 3 106) dose of LCMV cl-13.
(A) Representative dot plot of naive and memory P14 T cells in the spleen, liver, and lung at day 6.5 p.i.
(B) Numbers of naive and memory P14 T cells in the spleen at day 6.5 p.i.
(C) Percent of naive and memory P14 T cells in blood at day 6.5 p.i.
(D) Mice were set up as in (A)–(C) and were treated withMR1 antibody or PBS on day1, 0, 3, and 6 p.i. Numbers of naive andmemory P14 T cells in spleen at day
6.5 p.i.
In the figures and legends, +CD4 help indicates mice receiving Smarta cells; CD4 help indicates mice that do not receive Smarta cells. Results are repre-
sentative of two (D) or three (A–C) independent experiments with four to six mice per group. ***p < 0.005. Error bars represent SEM. See also Figure S4.
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Memory CD8+ T Cells in Acute and Chronic InfectionLCMV infection. To address this, we performed two sets of
experiments. In one experiment, we transferred a constant
number of naive or memory P14 T cells and varied the dose of
LCMV infection, and in the second, we varied the number of
naive and memory P14 T cells transferred and infected the(F and G) 23 103 wild-type (2B4-sufficient) or 2B4-deficient (Cd244/) naive and
on the following day the mice were infected with 2 3 106 pfu cl-13 i.v.
(F and G) Representative flow plots of P14s in the blood at day 7 p.i. (G) and num
Results representative of 12 mice per group (F and G). *p < 0.05, **p < 0.01, ***pmice with the chronic dose of LCMV cl-13. To begin, we trans-
ferred 3 3 104 naive or memory P14 T cells (3 3103 of each
cells after accounting for an10% take of the cells postinjection)
into mice that were subsequently infected with increasing doses
of LCMV cl-13 and assessed viral titers in the spleens at days 2,memory P14s (all Thy1.1+Thy1.2+) were individually transferred into mice and
ber of P14 T cells per 106 PBMC at days 7, 14, and 23 postinfection (F).
< 0.005 (F and G). See also Figure S3.
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Figure 6. The Ability of Naive and Memory Cells to Control LCMV Infection
(A andB) 33 104 ofmemory or naive P14 T cells were transferred into naive B6mice. The next day themicewere infectedwith 23 102, 23 104, 23 105, or 23 106
pfu of LCMV cl-13 i.v.
(A) Viral titer in the spleen on days 2, 3, and 5 p.i., as assayed by plaque assay on Vero E6 cells.
(B–D) 13 103, 13 104, 33 104, 13 105, or 2.53 105 naive or memory Thy1.1+ P14 T cells were transferred into naive mice. The next day mice were infected with
2 3 106 pfu of LCMV cl-13 i.v.
(B) Viral titer in the serum on days 4 and 8 p.i.
(C) Representative dot plots of naive and memory P14 T cells in the PBMC at day 8 p.i. with 2 3 106 pfu cl-13.
(D) Viral titer in the serum in mice receiving either no cells or 1 3 103 memory or naive P14 cells on day 14 p.i.
Results are representative of three to six mice per group per time point. *p < 0.05, ***p < .005, ns = p > 0.05.
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Memory CD8+ T Cells in Acute and Chronic Infection3, and 5 postinfection. By day 5 p.i., memory P14 T cells signif-
icantly decreased viral load in mice infected with 2 3 102 and
2 3 104 pfu of cl-13. However, in contrast, these low numbers
of memory and naive P14 T cells were incapable of reducing
virus levels in mice infected with higher and more persistent
doses of cl-13 (23 105 and 23 106) (Figure 6A). These data indi-
cate that on a per cell basis, memory cells are better than naive
cells at controlling acute or low-dose infections, but small
numbers of memory or naive cells are unable to control high-
dose and/or persistent infections.294 Immunity 35, 285–298, August 26, 2011 ª2011 Elsevier Inc.Next, to determine the ability of naive and memory cells to
control virus in the case of high viral load, we titrated the number
of memory and naive P14 CD8+ T cells that we transferred into
mice that were subsequently infected with a chronic dose
(2 3 106 pfu) of LCMV cl-13 and assessed viral titers in the
serum. No reduction in viremia was seen in any group at day 4
postinfection. However, by day 8 p.i., the transfer of greater
numbers of P14 T cells, 13 105 or 2.53 105, resulted in a larger
expansion ofmemory cells in the PBMC and increased reduction
of viral titers, in contrast to naive cell transfers (Figures 6B and
Immunity
Memory CD8+ T Cells in Acute and Chronic Infection6C). These data indicate that in cases where there are sufficient
numbers of functional memory cells to rapidly reduce or clear the
virus, memory CD8+ T cells are more efficient than naive cells. In
contrast, in instances with lower numbers of naive or memory
cells present, where virus was not quickly reduced, the naive
cells outnumberedmemory cells at day 8 postinfection, but there
was little effect on viral load by either naive or memory cells
(Figures 6B and 6C). By day 14 p.i., there was a small, but signif-
icant, decrease in the viral titers of the mice receiving 1 3 103
naive P14 T cells compared to memory cells (p = 0.0327) (Fig-
ure 6D), indicating that in some situations of high viral load where
virus is not rapidly eliminated, naive cells can bemore effective at
slightly reducing viral loads than memory cells. Taken together,
these data show that memory cells provide effective control of
low-dose infection and can provide control of high-dose infec-
tions in situations where they are present in large enough
numbers to rapidly control viral loads, thwarting the virus from
persisting. However, in instanceswherememory cells are unable
to quickly clear infection, the cells undergo regulatory mecha-
nisms and are rapidly lost.
DISCUSSION
In this study, we reveal the unexpected limitations of memory
CD8+ T cells in the context of high viral load or persistent antigen.
Memory cells provide quick and effective responses in the case
of short-lived antigen stimulation. However, in stark contrast, our
data show that memory cell function and survival is tightly regu-
lated during high antigen load or antigen persistence. Unlike
naive CD8+ T cells, memory cells havemore TCR signalingmole-
cules clustered at the TCR, increased loci accessibility of genes
involved in effector functions, and amplified immediate cytokine
production, creating a hyperresponsive state (DiSpirito and
Shen, 2010). Thus, increased regulation of memory cells com-
pared to naive cells may be an evolved mechanism to prevent
excessive immunopathology in the host. Two recent reports by
Hinrichs et al. show (1) that adoptive transfer of effector cells
derived from naive rather than memory CD8+ T cells mediate
superior antitumor immunity in a mouse model, and (2) that after
in vitro stimulation, effector cells derived from naive human CD8+
T cells have an increased proliferative capacity and are less
terminally differentiated than effectors derived from memory
human CD8+ T cells, and thus, primary effectors may be a supe-
rior cell population to use for adoptive immunotherapy (Hinrichs
et al., 2009, 2011). Our data support the concept that secondary
effectors are more terminally differentiated than primary CD8+
effector T cells during chronic antigen stimulation. An increased
expression of NK cell receptors are found on terminally differen-
tiated or senescent human T cells (Koch et al., 2007), and in
parallel, we found that NK cell receptors such as KLRG1 were
upregulated on secondary effectors during chronic infection.
Another property associated with senescence or terminal
differentiation is reduced proliferative capacity. In this study,
we demonstrate that virus-specific memory and naive CD8+
T cells are initially recruited similarly during situations of high
antigen load. However, in low-dose acute infection, the memory
cells already outnumber the naive cells at this time point, so this
may suggest that the memory cells are already undergoing regu-
latory mechanisms before, or as early as, day 4 postinfectionin situations of high-dose infection. Moreover, we show both
experimentally and by gene profiling that after this equal initial
recruitment of naive and memory cells, memory cells have less
proliferative capacity than naive cells early in chronic infection.
Thus, overall, constant antigen stimulation, like that seen in
a high-dose infection or antigen persistence, may quickly drive
memory cells to a more terminally differentiated state.
The data presented here show that both primary and sec-
ondary effector CD8+ T cells are prone to CD8+ T cell exhaustion
during chronic infection, as indicated by the microarray data and
the decreased ability of the cells to make cytokines as infection
progressed. Although the inhibitory receptors PD-1 and Lag-3
do not appear to play a role in the selective loss of secondary
effectors, our data implicate 2B4 as an immunomodulatory
molecule that regulatesmemory cell expansion or survival during
persistent antigen stimulation. Consistent with 2B4 mRNA and
protein being upregulated on exhausted CD8+ T cells during
chronic LCMV, increased surface expression on virus-specific
CD8+ T cells is found during human chronic diseases, such as
HCV, HBV, HIV, HTLV-1, and melanomas (Bengsch et al.,
2010; Casado et al., 2005; Enose-Akahata et al., 2009; Razior-
rouh et al., 2010; Tarazona et al., 2002). The role of 2B4 on
CD8+ T cell responses has not been well studied. In addition,
the dual stimulatory and inhibitory role that 2B4 is known to
play on NK cells further complicates our understanding of this
molecule (Chlewicki et al., 2008). 2B4 has been reported to be
positively correlated with good human CTL function (Rey et al.,
2006). Yet, in contrast, other studies indicate an inhibitory role
for 2B4 on CD8+ T cells in both human and mouse chronic infec-
tions (Bengsch et al., 2010; Blackburn et al., 2009; Raziorrouh
et al., 2010). Furthermore, work performed with natural killer
cells has shown that inhibitory function of 2B4 is related to
increased 2B4 expression, increased receptor crosslinking,
and lower expression of signaling lymphocyte activation mole-
cule-associated protein (SAP) (Chlewicki et al., 2008). Therefore,
the fact that our gene profiling of primary and secondary effector
CD8+ T cells at day 8 after acute and chronic LCMV infection
showed that Cd244 (2B4) is most highly upregulated on the
secondary effectors during chronic infection, and yet SAP
expression was similar among all cell classes (primary and sec-
ondary effectors in both acute and chronic infection), is consis-
tent with a negative regulatory role for 2B4 on memory cells
during antigen persistence. In conclusion, we have found an
important role for 2B4 in selectively affecting the survival and/
or expansion of secondary CD8+ T cell effectors during chronic
infection, implying that a better understanding of the role of
2B4 on CD8+ T cells is needed and may be helpful for vaccine
design.
Although it is well established that CD4+ T cell help is most
important during primary responses to create productive
memory cells, our work now highlights the selective increased
dependence of memory recall responses on CD4+ T cell help
in the context of antigen persistence. It is well known that
CD8+ T cells require CD4+ T cell help during some mouse and
human infections, including chronic infections (Harty and Bado-
vinac, 2008; Matloubian et al., 1994; Northrop and Shen, 2004;
Wherry, 2011; Williams et al., 2006). However, these studies
have mainly addressed the role of CD4+ T cell help during the
generation of primary CD8+ T cell responses and how this lossImmunity 35, 285–298, August 26, 2011 ª2011 Elsevier Inc. 295
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responses of these cells, rather than focusing on whether
CD4+ T cell help is important during memory recall responses.
Surprisingly, our data indicate that memory virus-specific
CD8+ T cell responses are more reliant on CD4+ T cell help
than naive virus-specific CD8+ T cell responses during antigen
persistence. These data indicate that CD4+ T cell help may be
an important component of vaccine strategy for chronic infec-
tions. Thus, there is a need to better understand the mechanism
and requirements for CD4+ T cell help of secondary CD8+ T cell
responses during chronic infection to aid in optimal vaccine
design for these infections.
These data presented in this paper have important implica-
tions in the design of T cell vaccines against chronic infections
and tumors. Although memory CD8+ T cells are much more
effective than naive cells at controlling various acute infections,
our data show that they are tightly regulated in situations of
high viral load or antigen persistence. When only low numbers
of antigen- and/or pathogen-specific memory CD8+ T cells
remain postvaccination, and when subsequent infection re-
sults in high doses of antigen or persistent antigen that is not
rapidly controlled, our data indicate that these memory cells
are unable to persist because of increased regulatory mecha-
nisms. Furthermore, these memory cells are more reliant on
CD4+ help, implying that an important component of vaccine
design in situations of high antigen chronicity may be the ability
to elicit and maintain large numbers of antigen-specific CD4+
T cells. However, our data also indicate that designing vaccines
which result in large pools of highly functional memory CD8+
T cells that rapidly lower antigen loads can provide viral control
of high-dose or persistent infections, an idea supported by
previous experiments in SIV and LCMV (Haase, 2010; Li et al.,
2009). Also, a recent vaccine study in the SIV model shows effi-
cacy when virus was rapidly controlled promptly after acquisition
(Hansen et al., 2011). In contrast, two recent human HIV clinical
trials, the Merck STEP trial and the RV144 Thai trial, show little
efficacy in reducing viral set-point during chronic infection
even though the RV144 trial shows some efficacy in decreased
acquisition of infection (Buchbinder et al., 2008; Rerks-Ngarm
et al., 2009). Taken together, these studies emphasize the impor-
tance of designing vaccines that quickly control or prevent
chronic infections. In cases where infection is rapidly controlled,
memory cells are unlikely to become subject to this tight regula-
tory control. Thus, the number and quality of memory CD8+
T cells elicited by a vaccine may greatly impact the success of
vaccines for high-dose or persistent infection. Furthermore,
designing vaccines that elicit large pools of CD4+ T cell help
and/or increasing strategies to overcome immunoregulation by
inhibitory receptors may be necessary for a successful vaccine
outcome.
EXPERIMENTAL PROCEDURES
Mice and Infections
Six-week-old female C57BL/6 mice were purchased from the Jackson
Laboratory. P14 TCR transgenic mice and Smarta TCR transgenic mice
were bred in-house. 2B4-deficient (Cd244/) P14 TCR transgenic mice
were made by breeding P14 TCR transgenic mice with Cd244 knockout
mice (CD244/). Cd244/ mice were generated on C57BL/6 ES cells
(Bruce 4) by replacement of exons 2 and 3 by a LoxP site and were kept on296 Immunity 35, 285–298, August 26, 2011 ª2011 Elsevier Inc.the C57BL/6 background (S.C., unpublished data). All Cd244/ P14 mice
were analyzed for P14 TCR expression and genotyped before use to make
sure that both alleles of 2B4 were interrupted. For acute infections, mice
were infected with either 2 3 105 pfu Arm i.p. or 2 3 102 pfu cl-13 i.v., unless
otherwise noted. For chronic infections, mice were infected with 2 3 106 pfu
cl-13 i.v. For persistent Ad-5 GP infection, mice were infected with 1010 vp
Ad-5 GP i.m. Ad-5 GP was kindly provided by G.A. Spies and M.J. McElrath
(Fred Hutchinson Cancer Research Center). Virus levels were assayed by pla-
que assays as previously described (Wherry et al., 2003a). All mice were used
in accordance with the Emory University Institutional Animal Care and Use
Committee Guidelines.
Cell Transfers
We created memory cells with the LCMV-specific TCR transgenic system as
described (Kaech et al., 2002a). In brief, we transferred a small number of
P14s (1 3 105), unless otherwise noted, and then infected the mice with
2 3 105 pfu Arm i.p. For the comparison of multiple vaccines/viruses,
1 3 104 P14 were transferred in to mice that were then infected with 2 3 105
pfu Arm LCMV i.p. or 13 106 pfu VV-33 i.p. or 109 vp of AD-5 GP i.m. Memory
cells were isolated at >45 days p.i. with CD8+ T cell isolation kit (Miltenyi
Biotech) or alternatively by sorting on CD8+Thy1.2CD62L+ or CD62L cells
on a BD FACS Vantage or BD Aria. 1 3 103 (or 5 3 103 for analysis at day 4
p.i.) of each memory and naive P14 T cells were transferred 1 day preinfection
into mice for all cotransfer experiments. 1 3 106 Smarta CD4+ T cells were
transferred after isolation from spleens of naive Smarta TCR transgenic mice
with a CD4+ T cell isolation kit (Miltenyi Biotech).
Lymphocyte Isolation and Flow Cytometry
Lymphocytes were isolated from the spleen, liver, lung, lymph nodes, IEL,
bone marrow, and blood as previously described (Barber et al., 2006; Maso-
pust et al., 2001). All antibodies were purchased from BD Biosciences (San
Diego, CA) except CD44, Thy1.1, and Thy1.2 (Biolegend) and anti-PD-1 and
anti-Tim-3 (eBioscience). MHC Class I tetramers were prepared and used as
previously described (Wherry et al., 2003a). Intracellular cytokine staining
was performed as previously described (Wherry et al., 2003a). Cells were
analyzed on a Canto or LSR II flow cytometer (BD Immunocytometry Systems).
Dead cells were excluded by gating on Live/Dead NEAR IR (Invitrogen).
In Vivo Blockade and Other In Vivo Treatments
For blockade of the PD-1 pathway, 200 mg of rat anti-mouse PD-L1 antibody
(10F.9G2 prepared in house) or rat IgG2b isotype control was administered
intraperitoneally (i.p.) on day 0, 3, and 6. For blockade of the Lag-3 pathway,
200 mg of rat anti-mouse Lag-3 (C9B7W from Biolegend) antibody was admin-
istered i.p. on day 0, 3, and 6. For blockade of CD40L (CD154), 500 mg of
hamster anti-mouse CD154 (MR1 from BioXcell) antibody was administered
i.p. on day 1, 0, 3, and 6.
Proliferation by In Vivo BrdU Incorporation
For assessment of proliferation by BrdU, mice were given 1 mg of BrdU i.p. at
day 6 and 8 p.i. and sacrificed 6 hr later. BrdU staining was carried out with
the APC or FITC BrdU Kit (BD Biosciences) according to manufacturer’s
instructions.
Microarray and Analysis
Day 8 primary and secondary effectors from acute and chronic LCMV-
infected mice were FACS sorted based on CD8+ and the congenic markers
Thy1.1 and Thy1.2. RNA was isolated with a RNeasy kit (QIAGEN) according
to manufacturer’s protocol. RNA was amplified, biotinylated, and three to
five samples of each cell type were hybridized on mouse 430.2 Affymetrix
microarray chips at the Vanderbilt Genome Sciences Resource (Vanderbilt
University, TN, USA). Prior to analysis, microarray data were preprocessed
and normalized with robust multichip averaging, as previously described
(Haining et al., 2008). Genes that are differentially expressed between two
classes were ranked with the GenePattern software package (Gould et al.,
2006). The statistical significance of differentially expressed genes and
hierarchical clustering was performed with GenePattern (Gould et al., 2006).
Gene set enrichment analysis (GSEA) was performed as described previously
(Subramanian et al., 2005).
Immunity
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All data were analyzed with Prism 5.0 (GraphPad).
Accession numbers
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.hih.gov/gds) under the accession number
GSE30962.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
doi:10.1016/j.immuni.2011.05.017.
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